Ten things you should know about protein kinases: IUPHAR Review 14

被引:249
作者
Fabbro, Doriano [1 ]
Cowan-Jacob, Sandra W. [2 ]
Moebitz, Henrik [2 ]
机构
[1] PIQUR Therapeut, CH-4057 Basel, Switzerland
[2] Novartis Inst Biomed Res, Basel, Switzerland
基金
英国惠康基金;
关键词
CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TYROSINE KINASE; SMALL-MOLECULE; BCR-ABL; ACQUIRED-RESISTANCE; SELECTIVE INHIBITOR; IRREVERSIBLE INHIBITORS; TARGETING KINASES; MAP KINASE;
D O I
10.1111/bph.13096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the 10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
引用
收藏
页码:2675 / 2700
页数:26
相关论文
共 296 条
  • [51] The role of protein phosphorylation in human health and disease - Delivered on June 30th 2001 at the FEBS Meeting in Lisbon
    Cohen, P
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (19): : 5001 - 5010
  • [52] Protein kinases - the major drug targets of the twenty-first century?
    Cohen, P
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 309 - 315
  • [53] The origins of protein phosphorylation
    Cohen, P
    [J]. NATURE CELL BIOLOGY, 2002, 4 (05) : E127 - E130
  • [54] Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases
    Comess, Kenneth M.
    Sun, Chaohong
    Abad-Zapatero, Cele
    Goedken, Eric R.
    Gum, Rebecca J.
    Borhani, David W.
    Argiriadi, Maria
    Groebe, Duncan R.
    Jia, Yong
    Clampit, Jill E.
    Haasch, Deanna L.
    Smith, Harriet T.
    Wang, Sanyi
    Song, Danying
    Coen, Michael L.
    Cloutier, Timothy E.
    Tang, Hua
    Cheng, Xueheng
    Quinn, Christopher
    Liu, Bo
    Xin, Zhili
    Liu, Gang
    Fry, Elizabeth H.
    Stoll, Vincent
    Ng, Teresa I.
    Banach, David
    Marcotte, Doug
    Burns, David J.
    Calderwood, David J.
    Hajduk, Philip J.
    [J]. ACS CHEMICAL BIOLOGY, 2011, 6 (03) : 234 - 244
  • [55] Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
    Converso, Antonella
    Hartingh, Timothy
    Garbaccio, Robert M.
    Tasber, Edward
    Rickert, Keith
    Fraley, Mark E.
    Yan, Youwei
    Kreatsoulas, Constantine
    Stirdivant, Steve
    Drakas, Bob
    Walsh, Eileen S.
    Hamilton, Kelly
    Buser, Carolyn A.
    Mao, Xianzhi
    Abrams, Marc T.
    Beck, Stephen C.
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Zugay-Murphy, Joan
    Sardana, Vinod
    Munshi, Sanjeev K.
    Jezequel-Sur, Sylvie Marie
    Zuck, Paul D.
    Hartman, George D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1240 - 1244
  • [56] PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
    Cools, J
    Stover, EH
    Boulton, CL
    Gotlib, J
    Legare, RD
    Amaral, SM
    Curley, DP
    Duclos, N
    Rowan, R
    Kutok, JL
    Lee, BH
    Williams, IR
    Coutre, SE
    Stone, RM
    DeAngelo, DJ
    Marynen, P
    Manley, PW
    Meyer, T
    Fabbro, D
    Neuberg, D
    Weisberg, E
    Griffin, JD
    Gilliland, DG
    [J]. CANCER CELL, 2003, 3 (05) : 459 - 469
  • [57] Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
    Cools, J
    Mentens, N
    Furet, P
    Fabbro, D
    Clark, JJ
    Griffin, JD
    Marynen, P
    Gilliland, DG
    [J]. CANCER RESEARCH, 2004, 64 (18) : 6385 - 6389
  • [58] Corcoran RB, 2011, ONCOTARGET, V2, P336
  • [59] The PI3K Pathway As Drug Target in Human Cancer
    Courtney, Kevin D.
    Corcoran, Ryan B.
    Engelman, Jeffrey A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1075 - 1083
  • [60] Structural biology of protein tyrosine kinases
    Cowan-Jacob, S. W.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (22) : 2608 - 2625